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Abstract
Background/Objective: Bone density loss occurs rapidly after traumatic spinal cord injury (SCI) and is
associated with low-energy fractures below the level of injury, commonly occurring around the knee.
Bisphosphonates have been tested as potential agents to prevent bone loss after SCI, but no guidelines exist
for clinical use of bisphosphonates in these patients. The objective of this study was to systematically review
and evaluate evidence quality in studies of bisphosphonate use in patients with post-treatment follow-up of
sublesional bone mineral density.
Methods: Literature search in MEDLINE/PubMed and ISI database using key words bisphosphonates, spinal
cord injury, quadriplegia, paraplegia, and tetraplegia.
Results: The search identified 6 experimental studies and 1 quasi-experimental study of bisphosphonate
therapy in patients with acute and chronic SCI. The studies were small and of fair or poor quality, and none
included fracture outcomes. Mild attenuation of bone density loss with acute administration of
bisphosphonates after SCI was found at some measurement sites but was not always maintained during
follow-up.
Conclusions: Data were insufficient to recommend routine use of bisphosphonates for fracture prevention
in these patients. Current studies are limited by heterogeneity of patient populations and outcome
measures. Uniform bone density measurement sites with rigorous quality control and compliance
monitoring are needed to improve reliability of outcomes. Future studies should address specific
populations (acute or chronic SCI) and should assess fracture outcomes.
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INTRODUCTION
Osteoporosis is a common and important complication of
spinal cord injury (SCI). Bone hyperresorption proceeds
rapidly after the onset of injury and predominantly affects
bones inferior to the level of the spinal cord lesion. In a
study of 99 persons with motor complete SCI who had
sustained a fragility fracture, bone mineral density (BMD)
losses of 54% in the distal femur and 73% in the distal
tibia occurred within the first 5 and 7 years after injury,
respectively (1). Low BMD is associated with increased
risk of fractures in persons with SCI (2). A study of 98
persons with paraplegia showed that the incidence of
fracture increased with the duration of time since injury,
from approximately 1% within the first year of injury to
4.6% in those with chronic SCI (20 to 29 years), with the
median duration to first fragility fracture occurring at 8.5
years (3). A recent Canadian population-based study of
individuals with SCI reported the prevalence of fractures
among persons with traumatic SCI to be 7.3% (4).
Complications of fractures include nonunion, infection,
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and skin ulcers, which can lead to further immobilization
and decreased functional independence. Because more
than one half of the 11,000 new cases of SCI reported in
the United States each year occur in individuals younger
than 30 years of age (5) and because the life expectancy
after SCI has dramatically increased to greater than 30
years after injury (4), the complications in the decades
after sustaining SCI constitute a significant disease
burden in this patient population.
Despite an understanding of the compromised bone
health after SCI, safe and effective diagnostic and
treatment strategies are unproven and difficult to test.
Standard osteoporosis diagnostic criteria (6), approaches
to fracture risk assessment (7), and BMD measurement
tools developed for postmenopausal women have not
been adequately tested in people with SCI and may not
be appropriate given the unique distribution of osteopo-
rosis and associated fractures, risk factors, and patho-
physiology of disease within the SCI population. World
Health Organization (WHO) diagnostic criteria for
osteoporosis were designed for postmenopausal women
(6); the relationship between WHO classification and
fracture risk for premenopausal women, young men, or
persons with an SCI is unknown. The distal femur and
proximal tibia have been proposed as sites for BMD
measurements in patients with SCI because they are the
most common sites of fracture after SCI (8–10). Hip BMD
has been found to moderately correlate with distal femur
BMD and is only marginally correlated with proximal tibia
BMD (9). Furthermore, standardized DXA protocols for
measurement of peripheral sites have not been available
for use in interventional studies to date (9). Finally,
according to the review by Giangregorio and McCartney
(11), data regarding the effectiveness of strategies to
build stronger bones around the knee through mechan-
ical stress, such as static loading (weight bearing by tilt
table), body weight–supported treadmill training, and
muscle contraction using functional electrical stimula-
tion, are inconclusive and require further study.
First- and second-generation bisphosphonates (BPs)
have been tested in small trials of persons with acute and
chronic SCI in an effort to attenuate bone hyper-
resorption by inhibiting osteoclastic activity (12). In
postmenopausal women, BPs confer a protective effect
against spine fractures that is clinically important (13)
and greater than expected for the small post-treatment
increases in BMD (14). Although BMD measures have
been examined in patients with SCI, the antifracture
efficacy with BPs in either the prevention or treatment of
sublesional osteoporosis after SCI is not yet characterized
(10).
This systematic review will summarize small random-
ized trials of BP treatment in persons with SCI with post-
treatment follow-up of sublesional BMD. The purpose is to
characterize patient populations tested, identify possible
trends in post-treatment BMD measures, and use this
information to provide direction for future research.
METHODS
The initial search strategy in the PubMed/MEDLINE
database (1966 through December 2008) made use of
key words bisphosphonates AND spinal cord injury OR
quadriplegia OR paraplegia and limited results to human
studies only, for a total yield of 134 articles. An additional
query using key words bisphosphonates AND paraplegic
OR tetraplegic identified 2 additional articles, but no new
relevant studies. To supplement the PubMed search, a
citation search was performed in the ISI database (1955
through December 2008) using key articles from the
bibliography of frequently cited studies; again, no new
relevant articles were found. References cited in review
articles were studied to assure adequacy of systematic
review.




BP therapy to optimize bone health
Primary outcomes: BMD, histomorphometry bone measures
Experimental study design (ie, randomized, controlled trial), quasi-experimental design (ie, nonrandomized trial), controlled




BP therapy for othera medical conditions
Cross-sectional studies, case series, case reports, expert opinion, reviews
a Heterotopic ossification, hypercalcemia secondary to immobilization or neoplasm, Paget’s disease of the spine, ankylosing
spondylitis, primary hyperparathyroidism, recurrent kidney stones.
BP, bisphosphonate; SCI, spinal cord injury; BMD, bone mineral density.
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On the basis of an exploratory search of the literature,
inclusion and exclusion criteria were established (Table
1). The study population was limited to persons with SCI
with specified or presumed traumatic etiology. The
primary outcome was BMD measured by dual-energy x-
ray absorptiometry (DXA) because clinically this is the
gold standard measure to assess fracture risk. The body of
literature on BP therapy in persons with SCI includes few
studies with rigorous study designs; therefore, broad
inclusion criteria for study design were set.
After a review of the title plus abstract or full text of
the article, articles that met all eligibility criteria were
selected. Three articles published before 1997 only
reported histomorphometric outcomes; these articles
were reviewed but were not assigned evidence ratings.
Data expressed as numbers and/or means and SDs or
95% confidence intervals (CIs) were retrieved for baseline
characteristics and BMD results. Intervention details were
also assessed, including type of drug and route, timing,
and frequency of administration. Main outcomes from
the studies using DXA measurements were BMD at
sublesional sites, considered clinically relevant because
they are common fracture sites in patients with SCI.
To establish minimum reference standards for the
quality of selected studies, the internal validity of each of
the included studies was assessed based on modified
quality assessment criteria for experimental trials (trials
that are randomized and include control/comparison
group) from the Centre for Reviews and Dissemination
(CRD 2001) (15). These criteria were developed by
consensus rounds by international experts who deter-
mined that 9 items comprised the key quality compo-
nents of experimental trials. The 9 items are referred to as
the Delphi list and consist of (a) randomization; (b)
adequate allocation concealment; (c) groups similar at
baseline; (d) specification of eligibility criteria; (e)
blinding of outcome assessor; (f) blinding of care
provider; (g) blinding of patient; (h) presentation of
point estimates and measures of variability for the
primary outcome; and (i) intention-to-treat analysis (16).
A subscore of 1 (inadequate or not reported), 2 (fair),
or 3 (good) was assigned for each category. All categories
had a minimum subscore of 1 except for the randomi-
zation category, in which a study received a 0 if it was not
randomized. Regarding item 3 on the Delphi list, because
similarity of baseline factors often cannot be achieved
with small sample sizes, and because the relative
importance of each prognostic factor for fracture risk is
not well established in persons with SCI, grades were not
significantly decreased if some baseline prognostic factors
were dissimilar in the treated and control groups. For
item 4, 1 point was subtracted from the subscore if either
inclusion or exclusion criteria were not specified, or an
additional point was subtracted for specified criteria that
were less rigorous. Separate CRD categories for blinding
(items 5–7) were not possible because no studies
reported blinding of the outcome assessor, care provider
and patient, only 2 of 7 reported blinding of the patient
and investigator, and the blinding methods were not
described in detail. Therefore, these categories were
combined into single subscore with a point given for
each type of blinding. Subscores were added to
determine overall evidence rating, with equal weights




Six randomized controlled trials (RCTs) and 1 quasi-
experimental study were identified as having BMD
measured by DXA as the primary outcome and were
published in 1997 and after. DXA was the only imaging
modality used in the studies. Although some studies
reported quality monitoring with DXA precision studies
(Table 2), the studies by Nance et al (20) and Gilchrist et
al measured DXA machine precision error on ambulatory
persons rather than persons with SCI.
Of the selected studies, 5 administered BPs in the
acute phase of SCI, 1 in the chronic phase, and 1 in the
acute and chronic phases (Table 2). When alendronate
was administered within 10 days of acute SCI and a
weekly 70-mg dose was continued for 12 months, BMD
declined at a slower rate in the treatment group, with a
resulting 7% difference (5.6 6 1% vs 12.7 6 1.4%; P
, 0.001) in the total body leg, and 17.6% difference
(3.3 6 0.9% vs 20.9 6 1.9%; P , 0.001) in the total
hip BMD, in the treatment group compared with placebo
controls (17). When a single dose of 4 or 5 mg of
zoledronic acid was administered within 10 to 12 weeks
after injury in a different study, bone loss was attenuated
at proximal femur sites for 6 months and at the femur
shaft for 12 months to a greater extent in the treatment
group compared with the placebo group (18). The
treatment effect did not persist at the proximal femur
site, however, because BMD values in both groups were
comparable at 12 months. BMD values at the femur shaft
were maintained near baseline up to 12 months in the
treatment group while decreasing in the placebo group.
In an older study with administration of a first-generation
BP, etidronate 800 mg daily 3 2 weeks (2 cycles 13 weeks
apart) starting within 6 weeks of SCI, BMD was
significantly decreased at 12 months (percentage loss at
12 months: 26% distal femur, 22% proximal tibia). A
treatment effect, with BMD being maintained near
baseline, was found only in the 2 patients who received
treatment and were ambulatory (19).
Two trials tested sequential administration of intra-
venous pamidronate over a 12-month period. One of
these trials tested pamidronate 30 mg administered every
4 weeks for 6 treatments. Results showed amelioration of
BMD loss at 12 months after injury in the treatment
group compared with the placebo group (6.8% vs 13.5%
mean overall BMD loss, respectively, P ¼ 0.11; 4.7% vs
10.8% distal femur, P ¼ 0.033) (20). However, the other
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Characteristics Study Design Intervention Supplement
Gilchrist et al N ¼ 31 RCT, PBO-controlled Alendronate 70 mg No calcium








Acute SCI (,10–12 wk)
Traumatic
C2–T12
Mean age: 30 y, 28 y
RCT, PBO-controlled Zoledronate 4 or 5 mg
Single dose at baseline
Diets reviewed to assure
adequate diet of calcium






Acute SCI (,11 wk, 6 wk)
Traumatic (not specified)
5 T, 6 P;
Mean age: 35 6 12 y
RCT, PBO-controlled Pamidronate 60 mg IV at
baseline and then at 1,
2, 3, 6, 9, and 12 mo
700þ mg calcium diet
(intake not monitored);
MVI with vitamin D
during rehab; later ad
libitum
Moran de Brito N ¼ 19 RCT, PBO-controlled Alendronate 10 mg/d 1,000 mg calcium/d
et al 2005 (22) Chronic SCI (61 mo, 38 mo)
Traumatic
ASIA A–C
12 P, 7 T
Mean age: 30.9 y, 30.8 y










Mean age: not specified
All male








Acute SCI (,6 wk)
Non-randomized,
PBO-controlled
Pamidronate 30 mg IV
once monthly
None
Traumatic (not specified) 3 6 mo
Motor incomplete/complete




Acute SCI (,6 wk)
RCT, PBO-controlled Etidronate, 800 mg/d
3 2 wk (2 cycles)




Mean age: 33 y, 35 y
12 Males, 1 Female












Total body, total arms,
total legs, trunk, pelvic
sites
12 mo: negative; negative at
total leg
DXA: Hologic and Lunar
phantoms scanned 3 times
weekly with overall precision
error in vitro 0.5%. Mean
precision error in vivo in
ambulatory adults 0.6% for
lumbar spine, 1.3% for total hip
Power calculations
12 mo: significant at total leg
(5.6 vs 12.7, P , 0.001)
18 mo (6 mo after cessation of
treatment): significant (P ,
0.001)
FS, IT, and FN 12 mo: negative
(nonsignificant); negative
(significant) at all 3 sites
DXA: standardized readings
between 2 machines using a 4-
step quality-control block
phantom for cross-calibration of
hip structure analysis method
12 mo: significant (exact values
and P values not reported) at
the IT and FS. Nonsignificant
at FN
Total leg, pelvis, DF, PT 6 mo: negative (significant),
rate of change different
12 mo: negative, rate
of change comparable
Phantom scanned 38 times over
12 mo, day-to-day variation
,1% (CV 0.06). 15 subjects
studied 4 times in 2 wk, day-to-
day variability ,1.5% (CV 1.49)
6 mo: significant at total leg
only (5 vs 9, P , 0.05)
24 mo: nonsignificant






chronic SCI: no significant
change in either group
DXA: NR 6 mo: not significant (0.01 6






24 mo: negative (maintained
near baseline); negative at
distal tibial epiphysis
DXA: quality control performed
daily with anthropomorphic
spine phantom, overall precision
error: 0.3% in vitro, 1.1% in vivo
for lumbar spine and hip
24 mo: significant at distal tibial
epiphysis (2.0 vs 10.8 P ¼
0.017), distal tibial diaphysis (P




12 mo: BMD values at the
hip were maintained near
baseline; negative
DXA: reproducibility study on
able-bodied persons showed
average variance of 0.0003
12 mo: significant (0.9 vs
8.2, P , 0.012 and 4.7 vs
10.8 DF P , 0.033) at the hip




12 mo: negative (significant
P , 0.05) in both groups
DXA: DF and PT measured using
a locally developed protocol,
quality assessment NR
12 mo: not significant (average
of both groups: 26 DF, 22
PT)
Average duration of injury (weeks for acute SCI), and as noted (months or years) for chronic SCI at the time of study entry of experimental group,
control group.
Mean age (years) of experimental group and control group.
Significant: P , 0.05.
RCT, randomized controlled trial; PBO, placebo-controlled; T, tetraplegic; P, paraplegic; DXA, dual-energy x-ray absorptiometry; IT, intertrochanteric;
FS, femoral shaft; FN, femur neck; DF, distal femur; PT, proximal tibia, DT, distal tibia; CV, coefficient of variation; NR, not reported.
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3 1 3 1
NR Age, sex, level of neurologic





Shapiro et al 3 1 2 2
2007 (18) ‘‘Random
number table’’




Exclusion: MAS . 3, prior BP
use, elevated creatinine,




1 1 3 1
Randomization
method NR




et al 2005 (22)
1 1 3 3
Randomization
method NR
NR Age, weight, sex. Attempted to
eliminate influence of voluntary
mobility with inclusion criteria.
Used age cut-offs to avoid
physiologic bone loss
Inclusion: ASIA A–C ,35 y old














Age, sex, BMI, calcium intake,
vitamin D level, testosterone level,
smoker, previous fragility fx
Inclusion: complete motor;
male age 18–60 y





0 1 2 3
Not randomized Not blinded Age, sex, level of neurologic
lesion








1 1 1 1
Randomization
method NR





bone fractures, bed traction
longer than 1 month, systemic
anticoagulation
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Table 3. Extended
Blinding of Caregiver,










1 3 1 13
‘‘Blinded observer’’ randomized
treatment groups
Mean and SEM, compared
treatment with control
2 2 1 13
Patient and
investigator blinded
Graphs of % BMD change
from baseline and 95% CI.
Some numeric values not
specified.
-NR
2 3 1 12
Patient and
investigator blinded
Mean and SD, compared
treatment with control
NR
1 3 1 12
NR Mean and SD, compared
treatment with control
1 3 1 13
Open-label study Mean and SEM, compared
treatment with control
Per protocol analysis
1 1 1 9
Not blinded Percent change, no error
reported
Initial recruitment numbers in
Table 1 do not match final
analysis numbers
1 1 1 7
NR Mean NR
BP, bisphosphonate; MAS . 3, modified Ashworth Scale of Spasticity, which denotes excessive spasticity; NR, not reported.
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trial of pamidronate 60 mg administered 7 times over 12
months showed that a significant treatment effect on
BMD did not persist relative to placebo in continued
follow-up at 24 months (19 6 17% vs28 6 10% distal
femur, 36 6 29% vs 42 6 14% proximal tibia) (21).
Administration of BPs to persons with chronic SCI
improved sublesional BMD loss relative to pretreatment
values, although statistical significance was only achieved
in 2 of 9 BMD parameters, and there was virtually no
variation in the lower extremity BMD values in the
treatment group relative to placebo (0.01 6 0.02% vs
0.01 6 0.05% lower extremity) (22). Administration of
10 mg daily oral alendronate plus elemental calcium to a
population of people with acute and chronic SCI for a
sustained period of 24 months showed a statistically
significant treatment effect (2.0 6 2.9% vs10.8 6 2.7%
distal tibia, P , 0.017) compared with calcium alone, but
not, on average, a reparation of bone loss relative to BMD
before SCI (23).
Selected Prognostic Factors
As noted above, factors independently associated with
osteoporosis in persons with SCI are not clearly estab-
lished, although conventional factors associated with
bone health in postmenopausal women may be consid-
ered (Tables 2 and 3). Age, weight, and sex are the most
important determinants of BMD (24,25), and these
factors were reported in all of the studies. Calcium and
vitamin D, which may also have independent effects on
BMD (17), were not consistently measured and were
coadministered with BPs in nearly all studies (Table 2).
Past BP use was an exclusion criterion in only one study
(20). An association between weight bearing and BMD
has been hypothesized, but these studies overall did not
show clear evidence regarding this prognostic factor. In
one study of administration of alendronate, BMD loss in
the proximal knee (distal femur) for ASIA A compared
with ASIA D was 12.5% vs 3% (20). In the study of
Pearson et al (19), which administered etidronate, a
significant interaction was seen between ambulation and
treatment status, and ambulation was found to have a
protective effect in treated individuals. The number of
ambulatory treated individuals was small (n ¼ 2),
however, and ambulation did not affect the BMD of the
control group. Spasticity, like ambulation, is a potential
source of mechanical stress on bone and therefore has
been postulated to have a protective effect on bone, yet
only one study took into account the degree of spasticity
in the patient population (18).
Evidence Ratings
Of the 7 studies with DXA BMD outcomes, 5 were rated
fair and 2 were rated poor in evidence quality. Grading
for each category is highlighted in the text and in
Table 3:
(a) Randomization method was not reported in any
studies except those by Shapiro et al (18) and
Gilchrist et al (17).
(b) Allocation concealment was not reported in any of
the randomized studies, and the study by Zehnder et
al (23) was open label.
(c) The more recent studies tended to be more rigorous
about reporting prognostic factors at baseline,
including age, sex, BMI, and a measure of calcium
and/or vitamin D levels.
(d) Regarding the eligibility criteria, the studies by
Gilchrist et al (17) and Zehnder et al (23) did not
specify eligibility criteria, and the study by Pearson et
al (19) did not specify inclusion criteria. Although the
study by Pearson et al (19) did specify exclusion
criteria, it failed to include pertinent criteria men-
tioned in other studies such as excessive spasticity
(Modified Ashworth Score .3), prior BP use, elevated
creatinine, chronic steroid use, active medical com-
plications, active heterotopic ossification, and preg-
nancy.
(e) Three criteria describing blinding of the patient,
observer and outcome assessor were combined into
1 category.
(f) All studies received a full or nearly full grade for point
estimates and measure of variability presented for the
primary outcome measure except for the 2 oldest
studies.
(g) No study performed or reported intention-to-treat
analysis.
Bone Histomorphometry Studies
Bone histomorphometry was the outcome measure cited
in 3 studies published before 1997 (26–28). One of these
studies reported no further decrease in bone mineral
content, and a second study reported a slight increase in
bone volume in samples from treated patients compared
with placebo controls.
DISCUSSION
In this review of RCTs and quasi-experimental studies,
treatment regimens of second-generation BPs adminis-
tered in the acute stages of SCI attenuated bone hyper-
resorption in treated patients compared with placebo
during the treatment period in most studies. However,
acute treatment failed to restore sublesional BMD to
preinjury levels and may not result in a long-term
therapeutic effect. A study of intravenous pamidronate
administered for 12 months showed no difference in
bone loss from baseline in treated patients vs controls by
24 months (12 months after treatment ended). The effect
size does not seem to be as significant when administered
in persons with chronic compared with acute SCI.
Methodological Considerations in the Studies
The overall quality assessment scores using the CRD
criteria showed poor or fair quality of the clinical studies.
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Although well-done RCTs can provide the best informa-
tion regarding the effectiveness of a medical intervention,
poorly designed trials may yield misleading results and
inconsistent findings in a systematic review. Therefore,
interpretation of findings from these studies must be
guarded.
Although 6 of the 7 studies used an experimental
design, the studies were too small to show the usual
strengths of large, randomized trials. Small sample sizes
yielded power sufficient for only marked changes in BMD
to be statistically significant; therefore, underestimation
of effect cannot be ruled out. For example, the power
calculations cited in the studies of Gilchrist et al (17) and
Zehnder et al (23) reported sufficient statistical power
(80%) to show a difference in bone loss of 7% per year or
more and 15% over 24 months at the 0.05 significance
level, respectively. Many studies failed to provide
adequate specification of the method of randomization
(lack of description regarding sequence generation for
randomization) and/or allocation concealment and failed
to perform intention-to-treat analysis. Additionally,
equivalence of baseline risk factors for bone loss in the
treatment and control groups was not possible to assess
in many studies because few patient characteristics were
reported. Small sample sizes likely precluded equal
distribution of risk factors in the 2 groups at baseline.
More detailed quality assessment showed several
potential confounders including varying administration
of calcium and vitamin D and variations in spasticity and
mobility in participants, all of which may have influenced
outcomes. An example of potential effects of mobility on
BMD was the greater BMD loss for patients with ASIA A
compared with patients with ASIA D in the study of
Nance et al (20), which suggested that nonambulatory
subjects receive less protective effect from treatment at
common fracture sites. Additionally, different dosing
regimens could have led to different outcomes in the
studies. Timing of the first dose of BP in acute SCI ranged
from 1.5 to 12 weeks after injury and differed by as much
as 5 weeks in the control and treatment groups within a
study. If weight-bearing activity is independently associ-
ated with BMD, changes in weight-bearing activity after
discharge from rehabilitation compared with during
rehabilitation or differential engagement in activity
between the treatment or placebo groups may have
affected outcomes. A recent study examining the level of
activity in persons with SCI after discharge from acute
inpatient rehabilitation showed that dynamic activities
decreased by one third (P , .001) and that this change
was independently associated with level and complete-
ness of lesion (29). Whether these potential confounders
and other sources of bias influenced findings toward or
away from the null hypothesis is difficult to ascertain.
Quality control measures such as multiple measure-
ments to determine precision of DXA machine and/or
having a single technician performing scans to avoid
interoperator variability were also not routinely incorpo-
rated, and compliance monitoring was not frequently
reported. Quality control of DXA measurements could
have affected the accuracy of results and are noted in
Table 2; however, this was not included in the evidence
ratings because it is not part of the CRD criteria.
In addition to assessing the quality of study methods,
outcome and quality improvement measures must be
judged for their clinical relevance to the specific
treatment population. The main outcome of most of
the studies reviewed is the percentage change in
sublesional BMD. Because the association between
sublesional BMD and fracture outcomes has not been
tested, this measure is of unknown clinical significance in
SCI. Generalizability of the reported outcomes is limited
by heterogeneity in the study performed on a mixed
population of persons with acute and chronic SCI and
heterogeneity of DXA measurement sites. Although most
studies using DXA measured BMD at the common
fracture sites (distal femur or proximal tibia) in the SCI
population, the studies by Gilchrist et al (17) and Shapiro
et al (18) failed to do so. This is likely not appropriate
given that performing DXA studies at the knee in the SCI
population can be challenging because of poor resolution
and difficulty with positioning caused by spasticity (9).
Additionally, imprecision is likely in longitudinal studies
that report a percentage change in BMD over time,
because there may be measurement error at each study
visit.
Limitations
Several limitations should be considered in the interpre-
tation of these findings. Results of a systematic review are
influenced by publication bias and bias caused by trial
design characteristics. Our evidence rating system gave
equal weight to the major Delphi criteria; this weighting
would not capture differential effects of individual
components of trial quality.
Clinical Implications and Future Studies
Certainly this patient population is at high risk of
accelerated bone loss often at an early age, and a better
understanding of effective interventions in the acute
setting before bone hyper-resorption would be beneficial
both to reduce the low-energy fracture incidence in
chronic SCI and to prevent fracture associated with
weight-bearing activities during physical rehabilitation to
optimize recovery after injury. However, given the
generally low internal validity of studies, poor statistical
power, lack of clinically relevant outcomes, and uncertain
generalizability, interpretation of findings is guarded. The
minimal evidence currently available does not provide
adequate justification for routine use of BP therapy for
prevention or treatment of BMD loss after SCI.
A major limitation of current studies in the SCI
population is that most BMD measurements were at
atypical anatomical sites with an unknown relationship to
fracture. Precision studies of DXA in patients with SCI will
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need to be performed to determine the least significant
change at the unique anatomical sites (distal femur and
proximal tibia) studied in SCI, and therefore, the percent
change that is outside the limits of machine precision.
Adopting a standardized DXA protocol for measurement
of common fracture sites, such as that proposed by
Shields et al, will facilitate direct comparison of outcomes
among studies and enhance generalizability, as well as
improve reliability of knee BMD measurements.
Current research in osteoporosis reinforces the view
that treatment should be directed on the basis of fracture
probability rather than on a single BMD threshold.
Research in persons with SCI must clarify the relative
importance of risk factors that might contribute or
protect against fracture risk, including level of injury,
sex, spasticity, and ambulatory status. A positive corre-
lation of BP therapy with ambulation was evident in some
studies. Because degree of ambulation could potentially
have an independent effect on BMD measures, larger
randomized studies with equivalent baseline ambulation
status in treatment and control groups should be
considered. Also, static loading or ambulation combined
with acute administration of BPs with a different dosing
schedule could be tested in patients with SCI.
In designing future studies, consideration should be
given to special factors in patients with SCI that warrant
concern about potential risks of BP use, especially in
pregnant women. BPs are FDA-approved for the treat-
ment of osteoporosis in postmenopausal women and
men and for treatment of glucocorticoid-induced osteo-
porosis. Caution must be exercised when using BPs in
women with SCI who are of reproductive age, because
BPs are a Category C drug and have a very long half-life
(eg, estimated half-life of alendronate is up to 12 years)
(30). Because BPs accumulate in the maternal skeleton,
cross the placenta, and accumulate in the fetal skeleton,
and because of reports of toxic effects in pregnant rats,
these agents are rarely used in women of reproductive
age (31). Two of the 7 studies reviewed cited pregnancy
or breastfeeding as an exclusion criterion (20,22).
Additionally, a case series of patients who sustained
unusual fractures after prolonged use of alendronate (32)
may have implications in young patients with traumatic
SCI, who could potentially take BPs for many years.
If warranted, prospective studies with long-term
follow-up and fracture incidence outcomes will be
necessary to better characterize the therapeutic effective-
ness of BPs and therefore facilitate evaluation of the cost-
benefit ratio of implementing therapy.
CONCLUSION
This systematic review identified 6 experimental studies
and 1 quasi-experimental study of BP therapy in acute
and chronic SCI. The studies were small and of fair or
poor quality, and none included fracture outcomes. Data
were insufficient to recommend routine use of BPs for
fracture prevention in these patients. Future research
should define risk factors associated with low-energy
fractures in the SCI population and should evaluate
whether the modest effect of bisphosphonates on BMD
in SCI is associated with fracture risk reduction. We
strongly recommend conducting future research within a
specific population (acute or chronic SCI) with consistent
timing of treatment administration to minimize hetero-
geneity in the study population. We also encourage
adoption of uniform outcome measures with rigorous
quality control and compliance monitoring to improve
reliability of outcomes.
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